Cornerstone Therapeutics Inc. (CRTX) reported third-quarter earnings per share of 7 cents, compared to a profit of 49 cents in the year-ago quarter. The Zacks Consensus Estimate was pegged at 1 cent.   Net revenues for the quarter were up 12.1% to $23.1 million as against $20.6 million in the year-ago quarter. Revenues were boosted by the acquisition of a few products during the quarter. Sales for two of the company’s products fell due to increased competition. Hyomax sales fell 39 %, to $7.6 million, while the AlleRx Dose Pack product line witnessed a 42 % decrease to $3.5 million.   On the positive side, revenues from Spectracef sales increased $1.9 million for the reported quarter primarily due to the enhanced promotion of the drug by Cornerstone’s sales force to targeted physicians.   Zyflo CR and Zyflo revenues came in at $5 million for the reported quarter.  Curosurf ...

Last week, Cornerstone Therapeutics Inc. (CRTX) announced the receipt of approval from the United States Bankruptcy Court for Massachusetts district regarding the acquisition of Factive's (gemifloxacin mesylate) commercial rights  in North America and some European countries from Oscient Pharmaceuticals Corp., which filed for Chapter 11 bankruptcy protection in July. The transaction is worth $5 million in cash. Additionally, it includes an amount for purchased inventory, quarterly royalty payments based on adjusted net sales for a period of five years, and the assumption of certain liabilities. Factive, which belongs to the fluoroquinolone class of antibiotics, is indicated for the treatment of community-acquired pneumonia (CAP) of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis (ABECB).  It was launched in the U.S. in September 2004 and is the only fluoroquinolone approved in the U.S. for the five-day treatment of both ABECB and CAP. Factive has generated ...

Last week, Cornerstone Therapeutics Inc. (CRTX) reported second quarter earnings of 13 cents per share, which was well below the Zacks Consensus Estimate of 33 cents. Net revenues for the quarter came in at $25 million, which reflected a 78% increase over the prior-year quarter. The company reported earnings of 31 cents per share in the previous year quarter. Operating expenses increased significantly in the quarter primarily due to increases in the workforce -- an increase in legal and accounting costs, costs associated with the Chiesi transaction, FDA regulatory-related fees, product liability, insurance-related costs, new product launches and royalties on increased product sales. As a reminder, Cornerstone Therapeutics Inc. was established through the merger of Critical Therapeutics with Cornerstone Biopharma Holdings Inc. in the fourth quarter of 2008. The financial statements for periods prior to the merger reflect the historical results of Cornerstone BioPharma, not ...

Cornerstone Therapeutics, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. The company is dedicated to making quality medicines in order to improve the quality of life.

Cornerstone offers trusted medications such as Zyflo CR®, Spectracef® and AlleRx®. Zyflo CR® is an extended release oral medication that is used to prevent and treat asthma in adults and children 12 years and older. Infections caused by bacteria can be treated with Spectracef®, while those suffering from allergies will find relief by taking AlleRx®.

Cornerstone has successfully alienated themselves from their competitors by partnering with leading domestic and international pharmaceutical companies. Through strategic planning, the company aims to maximize the potential value and competitive position of its currently marketed products, newly acquired products and product candidates that are currently in development.

Let us hear your

...

DrStockPick.com Stock Report!

Tuesday August 11, 2009

**************************************************************

WABCO Holdings Inc. (NYSE: WBC) (www.wabco-auto.com), a global technology leader and tier-one supplier to the commercial vehicle industry, today announced that WABCO and Ashok Leyland, the Indian flagship of the Hinduja Group, have completed an agreement for development of transmission automation technology and the long term supply of automated manual transmission (AMT) systems from 2010 through 2015.

TeleCommunication Systems, Inc. (NASDAQ: TSYS), a leading provider of mission-critical wireless communications, today clarified the first office action (FOA) issued last week by the U.S. Patent & Trademark Office in its inter partes re-examination of U.S. Patent No. 6,985,748, titled “Inter-Carrier Short Messaging Service Providing Phone Number

...

On July 15, 2009, North Carolina-based specialty pharma company Cornerstone Therapeutics Inc. (CRTX) announced the submission of a regulatory filing with the  US Food and Drug Administration (FDA) for an extended-release antitussive (cough suppressant) product, CRTX 067. On approval, it will compete directly in the narcotic antitussive market, which includes big players like Covidien (COV) and UCB. The company expects the product to hit the US market by 2011.

According to Wolters Kluwer Health, in 2008, there were over 30 million prescriptions generated for oral antitussive and antitussive combinations. Nearly 10 million of these prescriptions were for products that only contained a narcotic antitussive and an antihistamine.

The drug has a huge market opportunity since cough can adversely affect the quality of life, leading patients to seek medical attention. Most antitussive and antitussive combination products currently in the market must be dosed every four to six hours, which can be

...

Cornerstone Therapeutics Inc (CRTX), a North Carolina-based specialty pharma company, got into a definitive asset purchase agreement with biopharmaceutical company Oscient Pharmaceuticals Corp. (OSCI) on July13, 2009. Under the agreement, CRTX agreed to purchase the commercial rights of Factive (gemifloxacin mesylate) for $5 million in North America and some European countries from OSCI, which has filed for Chapter 11 bankruptcy protection. Subsequently, the bankruptcy court is expected to pass its verdict within the next two months. Factive is indicated for the treatment of community-acquired pneumonia (CAP) of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis (AECB).  Factive belongs to the fluoroquinolone class of antibiotics. It received FDA approval in May 2007 for the five-day treatment of CAP. Cornerstone Therapeutics currently promotes its products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone also ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Achillion Pharmaceuticals Inc (ACHN) Allied World Assurance Holdings Ltd (AWH) Altra Holdings Inc (AIMC) Ambassadors Group Inc (EPAX) AP Pharma Inc (APPA) Atlas Air Worldwide Holdings Inc (AAWW) Big 5 Sporting Goods Corp (BGFV) Brink's Home Security Holdings Inc (CFL) Bway Holding Co (BWY) Cambrex Corp (CBM) Carrols Restaurant Group Inc (TAST) Cornerstone Therapeutics Inc (CRTX) Cubic Corp (CUB) DSP Group Inc (DSPG) DuPont Fabros Technology Inc (DFT) Electronic Arts Inc (ERTS) Hydrogenics Corp (HYGS) Iconix Brand Group Inc (ICON) ICU Medical Inc (ICUI) Ikanos Communications Inc (IKAN) iPass Inc (IPAS) Kona Grill Inc (KONA) The Laclede Group Inc (LG) Linn Energy LLC (LINE) Macrovision Solutions Corp (MVSN) Meadowbrook Insurance ...

For Immediate Release

Chicago, IL - March 31, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Ness Technologies (NSTC), American Capital Agency Corp (AGNC), Biogen Idec (BIIB), Sohu.com Inc (SOHU) and Cornerstone Therapeutics Inc (CRTX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday's Analyst Blog:

Ness Tech with More Downside

Ness Technologies (NSTC) is a small player in the IT services market. The company posted mixed 4Q08 results, with revenue below expectation but in line EPS.

The company's Application Development and Software Product Engineering segment performed very well in 4Q08. However,

...

Cornerstone Pharma Gets New Lease on LifeCornerstone Therapeutics, Inc. (CRTX) is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. Cornerstone Therapeutics is a newly created company following the merger of private Cornerstone BioPharma with public Critical Therapeutics completed on October 31, 2008. The merged company gets a new lease on life, finally.Merger Positive for Both Companies We think the merger makes sense and is positive to both old companies. For Critical Therapeutics, the merger has greatly expanded its product portfolio, provided better resources for operations and sustainable growth. Critical Therapeutics was a tiny biotech company with only one product -- Zyflo/Zyflo CR -- on the market, with a very weak pipeline. Sales of Zyflo/Zyflo CR have been slow and the company had been under great pressure to expand its portfolio.The merger with ...